Multiple sclerosis: Relating MxA transcription to anti-interferon-β-neutralizing antibodies
- 20 March 2007
- journal article
- Published by Wolters Kluwer Health in Neurology
- Vol. 68 (12), 958-959
- https://doi.org/10.1212/01.wnl.0000257128.53775.62
Abstract
We collected serum and PAXgene (PreAnalytiX/Qiagen, Hilden, Germany) samples from 81 patients with relapsing-remitting MS (RR-MS) (54 women, 27 men, median age 38, Expanded Disability Status Scale [EDSS] median 2.0, range 0 to 6.5) before (n = 62) and 12 to 24 hours after (n = 71) injection of IFNβ (Avonex, n = 12; Rebif, 3 × 22 μg, n = 13; Rebif, 3 × 44 μg, n = 39; Betaferon, n = 17). Treatment duration was >6 months in all cases. We also collected blood samples from 25 untreated control patients with RR-MS (19 women, 6 men, median age 32 years, EDSS median 2.0, range 0.0 to 5.0). We analyzed transcription of MxA and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) as housekeeping gene by TaqMan …Keywords
This publication has 7 references indexed in Scilit:
- Persistence of neutralizing antibodies after discontinuation of IFNβ therapy in patients with relapsing-remitting multiple sclerosisMultiple Sclerosis Journal, 2006
- Multiplex analysis of expression of three IFNβ-induced genes in antibody-positive MS patientsNeurology, 2006
- The importance of measuring IFNβ bioactivity: Monitoring in MS patients and the effect of anti-IFNβ antibodiesJournal of Neuroimmunology, 2005
- Neutralizing antibodies to disease-modifying agents in the treatment of multiple sclerosisNeurology, 2004
- Clinical importance of neutralising antibodies against interferon beta in patients with relapsing-remitting multiple sclerosisThe Lancet, 2003
- Parkinsonian signs in older peopleNeurology, 2003
- Measurement of Antibodies to Interferon Beta in Patients With Multiple SclerosisArchives of Neurology, 2001